Indaptus Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Indaptus Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow JonesJun 17 06:50 ET

Indaptus Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 395.87% HC Wainwright & Co. $12 → $12 Reiterates Buy → Buy 04/15/2024 395.87% HC Wainwright & C

BenzingaJun 17 06:39 ET

H.C. Wainwright Maintains Indaptus Therapeutics(INDP.US) With Buy Rating, Maintains Target Price $12

H.C. Wainwright analyst Ram Selvaraju maintains $Indaptus Therapeutics(INDP.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of

moomoo NewsJun 17 06:33 ET · Ratings

EClinical Solutions to Highlight Successful Approaches for AI-Driven Clinical Trial Productivity at Citeline Roundtable, DIA, and More

Company will share clinical data transformation expertise alongside other life science heavyweights, as part of busy summer events circuitBOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global pro

BusinesswireJun 12 12:00 ET

Express News | Indaptus Therapeutics To Present At STING & TLR-Targeted Therapies Summit Jun. 19-20

BenzingaJun 11 08:07 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersVenus Concept (NASDAQ:VERO) shares increased by 135.2% to $1.38 during Friday's pre-market session. The market value of their outstanding shares is at $8.7 million. Adlai Nortye (NASDAQ:ANL) sh

BenzingaJun 7 08:08 ET